Dihydromyricetin reverses capecitabine‐induced peripheral myelin dysfunction through modulation of oxidative stress

Jie Fang,Shuyi Lou,Xinyi Zhou,Dayong Lou,Liqin Zhou,Rong Bian

DOI: https://doi.org/10.1111/1440-1681.13833

2024-01-11

Clinical and Experimental Pharmacology and Physiology

Abstract:Abstract Previous clinical reports have shown that capecitabine, an oral prodrug of 5‐fluorouracil (5‐Fu), can induce peripheral neuropathy, resulting in numbness, paresthesia and hypoesthesia. However, the mechanism through which capecitabine causes peripheral nerve injury remains unclear. Here, we demonstrate that systemic administration of capecitabine leads to myelin abnormalities in the peripheral nerves of mice, which are possibly attributed to the death of Schwann cells, the myelinating cells in the peripheral nervous system. Furthermore, our results show that 5‐Fu induces significant oxidative stress in Schwann cells by inhibiting the expression of the anti‐oxidative protein DJ‐1, leading to a decrease in Schwann cell markers. We found that the anti‐oxidant dihydromyricetin (DMY) reverses 5‐Fu‐induced Schwann cell death and oxidative stress and alleviates capecitabine‐induced myelin abnormalities. Taken together, our data indicate that capecitabine induces peripheral myelin dysfunction by regulating DJ‐1‐mediated oxidative stress in Schwann cells and reveal DMY as a potential therapeutic strategy for capecitabine‐induced peripheral neuropathy.

pharmacology & pharmacy,physiology